

Supplement Table S1. Baseline characteristics between included (follow-up) and excluded patients (follow-up loss)

Characteristic	Included patients (n = 99)	Excluded patients (n = 66)	P-value
Age (yr)	83.3 ± 3.168	84.0 ± 3.2	0.559
Body mass index (kg/m ²)	21.6 ± 2.8	22.2 ± 3.6	0.269
Sex			0.017
Male	61 (61.6)	28 (42.4)	
Female	38 (38.4)	38 (57.6)	
Diabetes mellitus			0.714
(-)	81 (82.7)	54 (81.8)	
(+)	17 (17.3)	12 (18.2)	
Hypertension			0.875
(-)	49 (50.0)	32 (48.5)	
(+)	49 (50.0)	34 (51.5)	
ASA score			0.509
Score 1, 2	79 (81.4)	53 (86.9)	
Score ≥ 3	18 (18.6)	8 (13.1)	
Location			0.444
Colon	80 (80.8)	50 (75.8)	
Rectum	19 (19.2)	16 (24.2)	
CEA (ng/mL)			1.000
< 5	70 (75.3)	47 (74.6)	
≥ 5	23 (24.7)	16 (25.4)	
Tumor grade			0.809
Low	87 (87.9)	59 (89.4)	
High	12 (12.1)	7 (10.6)	0.179
Tumor size (cm)	5.13 ± 2.32	5.67 ± 2.58	
Venous invasion			> 0.99
(-)	83 (94.3)	32 (95.2)	
(+)	5 (5.7)	3 (4.8)	
Perineural invasion			0.615
(-)	73 (85.9)	50 (89.3)	
(+)	12 (14.1)	6 (10.7)	
Lymphatic invasion			0.209
(-)	66 (69.5)	52 (78.8)	
(+)	29 (30.5)	14 (21.2)	
Stage			0.755
0, 1	20 (20.2)	13 (19.7)	
2	41 (41.4)	31 (47.0)	
3	38 (38.4)	22 (33.3)	
Adjuvant therapy			0.080
(-)	74 (74.7)	57 (86.4)	
(+)	25 (25.3)	9 (13.6)	

Values are presented as mean ± standard deviation or number (%).